Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PTLD in HCV-Positive Transplant Recipients Studied

Leuk Lymphoma; ePub 2017 Dec 18; Alderuccio, et al

Patients with hepatitis C virus+ post-transplant lymphoproliferative disorder (PTLD) appear to experience decreased survival following liver transplant/immunochemotherapy, according to a study involving nearly 1,500 liver transplant recipients. Investigators looked at PTLD incidence at a single institution over a 10-year period ending in 2016. Among the results:

  • PTLD developed in 20 patients, an incidence rate of 1.3%.
  • HCV caused PTLD in half of those who developed it.
  • Diffuse large B-cell lymphoma—the most frequent histologic subtype—occurred in 17 patients; all of those evaluated achieved complete remission.
  • HCV+ patients experienced statistically significant decreased survival.
  • 6 patients had increased HCV RNA during therapy.
  • 4 developed graft failure, 3 of whom died from liver dysfunction.

Citation:

Alderuccio J, Stefanovic A, Dammrich D, et al. Decreased survival in hepatitis C patients with monomorphic post-transplant lymphoproliferative disorder after liver transplantation treated with frontline immunochemotherapy. [Published online ahead of print December 18, 2017]. Leuk Lymphoma. doi:10.1080/10428194.2017.1413187.